Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Newborns with PPHN
NCT01069861Phase 2Terminated
- Sponsor
- Viatris
- Start
- Dec 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sildenafil in persistent pulmonary hypertension of the newborn (PPHN), sponsored by Viatris. Primary endpoints: Percentage of Participants Requiring Inhaled Nitric Oxide (iNO) or Extracorporeal Membrane Oxygenation (ECMO) at Day 14, Number of Participants With Adverse Events (AEs) Based on Severity and 1 more. Started Dec 2010; status: terminated.
02
Drugs
sildenafil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on NCT01069861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069861.